73 related articles for article (PubMed ID: 754366)
1. Inhibitors of neovascularization in relation to diabetic and other proliferative retinopathies.
Patz A; Lutty G; Bennett A; Coughlin WR
Trans Am Ophthalmol Soc; 1978; 76():102-7. PubMed ID: 754366
[TBL] [Abstract][Full Text] [Related]
2. Retinal detachment associated with proliferative retinopathies (sickle cell disease, retrolental fibroplasia and diabetes mellitus).
Goldberg MF
Isr J Med Sci; 1972; 8(8):1447-57. PubMed ID: 4567302
[No Abstract] [Full Text] [Related]
3. Oxygenation and vasodilatation in relation to diabetic and other proliferative retinopathies.
Stefansson E; Landers MB; Wolbarsht ML
Ophthalmic Surg; 1983 Mar; 14(3):209-26. PubMed ID: 6190118
[TBL] [Abstract][Full Text] [Related]
4. The rationale of photocoagulation therapy for proliferative diabetic retinopathy: a review and a model.
Wolbarsht ML; Landers MB
Ophthalmic Surg; 1980 Apr; 11(4):235-45. PubMed ID: 6155650
[TBL] [Abstract][Full Text] [Related]
5. Cyclooxygenase-2 in human and experimental ischemic proliferative retinopathy.
Sennlaub F; Valamanesh F; Vazquez-Tello A; El-Asrar AM; Checchin D; Brault S; Gobeil F; Beauchamp MH; Mwaikambo B; Courtois Y; Geboes K; Varma DR; Lachapelle P; Ong H; Behar-Cohen F; Chemtob S
Circulation; 2003 Jul; 108(2):198-204. PubMed ID: 12821538
[TBL] [Abstract][Full Text] [Related]
6. Management of proliferative diabetic retinopathy.
Gündüz K; Bakri SJ
Compr Ophthalmol Update; 2007; 8(5):245-56. PubMed ID: 18201511
[TBL] [Abstract][Full Text] [Related]
7. Prolonged tumor dormancy by prevention of neovascularization in the vitreous.
Brem S; Brem H; Folkman J; Finkelstein D; Patz A
Cancer Res; 1976 Aug; 36(8):2807-12. PubMed ID: 1277191
[TBL] [Abstract][Full Text] [Related]
8. Components of vitreous-soluble proteins: effect of hyperoxia and age.
Chen CH; Patz A
Invest Ophthalmol; 1976 Mar; 15(3):228-32. PubMed ID: 1254412
[TBL] [Abstract][Full Text] [Related]
9. Diabetic patients and retinal proliferation: an evaluation of the role of vascular endothelial growth factor (VEGF).
Nicoletti VG; Nicoletti R; Ferrara N; Meli G; Reibaldi M; Reibaldi A
Exp Clin Endocrinol Diabetes; 2003 Jun; 111(4):209-14. PubMed ID: 12845559
[TBL] [Abstract][Full Text] [Related]
10. Vitreous levels of the insulin-like growth factors I and II, and the insulin-like growth factor binding proteins 2 and 3, increase in neovascular eye disease. Studies in nondiabetic and diabetic subjects.
Meyer-Schwickerath R; Pfeiffer A; Blum WF; Freyberger H; Klein M; Lösche C; Röllmann R; Schatz H
J Clin Invest; 1993 Dec; 92(6):2620-5. PubMed ID: 7504689
[TBL] [Abstract][Full Text] [Related]
11. [Vitreoretinal changes after photocoagulation treatment of proliferative retinopathies].
Bacin F
Bull Soc Ophtalmol Fr; 1983 Apr; 83(4):563-6. PubMed ID: 6685000
[No Abstract] [Full Text] [Related]
12. Differential expression of vitreous proteins in proliferative diabetic retinopathy.
Kim SJ; Kim S; Park J; Lee HK; Park KS; Yu HG; Kim Y
Curr Eye Res; 2006 Mar; 31(3):231-40. PubMed ID: 16531280
[TBL] [Abstract][Full Text] [Related]
13. Proliferative retinopathies: angiogenesis that blinds.
Sapieha P; Hamel D; Shao Z; Rivera JC; Zaniolo K; Joyal JS; Chemtob S
Int J Biochem Cell Biol; 2010 Jan; 42(1):5-12. PubMed ID: 19836461
[TBL] [Abstract][Full Text] [Related]
14. Intraocular adenoviral vector-mediated gene transfer in proliferative retinopathies.
Mori K; Gehlbach P; Ando A; Wahlin K; Gunther V; McVey D; Wei L; Campochiaro PA
Invest Ophthalmol Vis Sci; 2002 May; 43(5):1610-5. PubMed ID: 11980881
[TBL] [Abstract][Full Text] [Related]
15. Angiotensin converting enzyme inhibiting therapy is associated with lower vitreous vascular endothelial growth factor concentrations in patients with proliferative diabetic retinopathy.
Hogeboom van Buggenum IM; Polak BC; Reichert-Thoen JW; de Vries-Knoppert WA; van Hinsbergh VW; Tangelder GJ
Diabetologia; 2002 Feb; 45(2):203-9. PubMed ID: 11935151
[TBL] [Abstract][Full Text] [Related]
16. Intraocular injection of an aptamer that binds PDGF-B: a potential treatment for proliferative retinopathies.
Akiyama H; Kachi S; Silva RL; Umeda N; Hackett SF; McCauley D; McCauley T; Zoltoski A; Epstein DM; Campochiaro PA
J Cell Physiol; 2006 May; 207(2):407-12. PubMed ID: 16419035
[TBL] [Abstract][Full Text] [Related]
17. Fractalkine, a CX3C chemokine, as a mediator of ocular angiogenesis.
You JJ; Yang CH; Huang JS; Chen MS; Yang CM
Invest Ophthalmol Vis Sci; 2007 Nov; 48(11):5290-8. PubMed ID: 17962485
[TBL] [Abstract][Full Text] [Related]
18. Diabetes and retinal vascular disorders: role of the renin-angiotensin system.
Wilkinson-Berka JL
Expert Rev Mol Med; 2004 Jul; 6(15):1-18. PubMed ID: 15387897
[TBL] [Abstract][Full Text] [Related]
19. [The morphologic structure of vitreous hemorrhage and posterior vitreous detachment].
Weng N; Wei W; Zhu X
Zhonghua Yan Ke Za Zhi; 2001 Nov; 37(6):425-7. PubMed ID: 11840748
[TBL] [Abstract][Full Text] [Related]
20. Growth factors and diabetic retinopathy.
Paques M; Massin P; Gaudric A
Diabetes Metab; 1997 Apr; 23(2):125-30. PubMed ID: 9137900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
